Care
home residents and workers
80+
and health/social care workers
All
those 75+
All
those 70+
All
those 65+
High-
risk adults under 65
Moderate-
risk adults under 65
All
those 60+
All
those 55+
All
those 50+
Rest
of population
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
% of total population by priority group (based on U.K. priority grouping)
1%
5%
3%
5%
6%
4%
8%
6%
6%
5%
51%
% of population with vaccine-induced immunity by deal under scenario B assumptions:
Moderna
1%
3%
2%
3%
4%
1%
0%
0%
0%
0%
0%
BioNTech/Pfizer
1%
3%
2%
3%
4%
1%
0%
0%
0%
0%
0%
Johnson & Johnson (Janssen)
1%
3%
2%
3%
4%
3%
5%
4%
4%
3%
27%
Oxford/AstraZeneca
1%
3%
2%
3%
4%
3%
5%
4%
4%
3%
0%
Novavax
1%
3%
2%
3%
4%
3%
5%
4%
4%
3%
27%
Sanofi/GSK
1%
3%
2%
3%
4%
3%
5%
4%
4%
3%
24%
Valneva
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Total across all deals
1%
3%
2%
3%
4%
3%
5%
4%
4%
3%
32%